FDA's Janet Woodcock |
Pharma marketers are closely watching Amarin's ($AMRN) lawsuit demanding the right to talk up off-label uses for its cardiovascular drug Vascepa. After all, if the legal attack against FDA regulations succeeds, that gives credence to drugmakers' free speech argument--and could open up new worlds of drug promotion. The FDA knows this. And it's fighting back, if obliquely. Report